Epidemiology and Treatment Aspects of Hair Loss in India – A Cross-Sectional, Multicentre, Database Study (HAILO)
Published: 2023-05-10
Page: 22-32
Issue: 2023 - Volume 6 [Issue 1]
G. Monil *
Department of Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India.
M. Snehal
Department of Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India.
Krishna C. Veligandla
Department of Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India.
R. Rahul
Department of Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India.
D. Gauri
Department of Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India.
K. Bhavesh
Department of Medical Affairs, Dr. Reddy’s Laboratories Ltd., Hyderabad, Telangana, India.
S. Snehal
Department of Clinical Insights, Healthplix Technologies, Bengaluru, India.
*Author to whom correspondence should be addressed.
Abstract
Aims: To evaluate the demography and treatment patterns for Indian patients with hair loss.
Study Design: An electronic medical record (EMR)-based, retrospective, multicenter, cross-sectional study.
Place and Duration of Study: EMR records between June 2018 and June 2021.
Methodology: Data of patients ≥12 years of age with reported hair loss secondary to any cause was included. Informed consent waiver was obtained from ethics committees as this is a non-experimental, retrospective data analysis study. Demographic and treatment details of patients sub-grouped based on type of hair loss were noted.
Results: Data of 24595 patients diagnosed with hair loss were evaluated. Telogen effluvium (TE) was the commonest reason for hair fall (40.70%), followed by female pattern hair loss (FPHL) (22.09%), alopecia areata (AA) (12.81%), and male pattern hair loss (MPHL) (7.49%). Majority cases were females (n=10794, 74.8%), with most belonging to 12-39 years’ age group (n=11734). Commonest comorbidity noted was acne (10.4%), followed by seborrheic dermatitis (3.0%). Overall, 1658 (12.31%) continued same treatment at follow-up, 956 (7.10%) patients had an add-on of new formulation, and 975 (7.24%) cases had a change of treatment. Overall, nutritional supplements were most adopted by physicians at baseline (n=6843), while pharmacological agents were the therapy of choice at follow-up (17.41%). For MPHL, FPHL and AA groups commonest treatment option at both baseline and follow-up was pharmacological agent; for TE group, commonest treatment option at baseline was nutritional supplements, and pharmacological therapy at follow-up. The most common class of therapy prescribed as a substituted agent at follow-up was nutritional supplements for all hair-loss subgroups.
Conclusion: Hair loss was caused by various causes, with TE and FPHL noted to be more common. Young to middle-aged females were noted to be most affected by hair loss. Though pharmacological agents remain the key choice for managing hair loss, substitution or addition of nutritional supplements was noted commonly at follow-up.
Keywords: Androgenetic alopecia, telogen effluvium, male pattern hair loss, female pattern hair loss, alopecia areata
How to Cite
References
Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189-99.
Ho CH, Sood T, Zito PM. Androgenetic alopecia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Shankar DK, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: Population-based study in 1,005 subjects. Int J Trichol 2009;1(2):131-3.
Price VH. Androgenetic alopecia in women. J Invest Dermatol Symp Proc. 2003;8(1):24-7.
Tobin DJ, Gunin A, Magerl M, Handijski B, Paus R. Plasticity and cytokinetic dynamics of the hair follicle mesenchyme: Implications for hair growth control. J Invest Dermatol. 2003;120(6):895-904.
Messenger AG. Hair through the female life cycle. Br J Dermatol 2011;165:2-6.
Singal A, Sonthalia S, Verma P. Female pattern hair loss. Indian J Dermatol Venereol Leprol. 2013;79(5):626-40.
Kaliyadan F, Nambiar A, Vijayaraghavan S. Androgenetic alopecia: An update. Indian J Dermatol Venereol Leprol. 2013; 79(5):613-25.
Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata - Current understanding and management. J Dtsch Dermatol Ges. 2022;20(1):59-90.
Mostaghimi A, Napatalung L, Sikirica V, Winnette R, Xenakis J, Zwillich SH, et al. Patient perspectives of the social, emotional and functional impact of alopecia areata: A systematic literature review. Dermatol Ther (Heidelb). 2021; 11(3):867-83.
Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017; 3:17011.
Malkud S. Telogen effluvium: A Review. J Clin Diagn Res. 2015;9(9):WE01-03.
Messenger AG, Berker DA, Sinclair RD. Rook’s text book of dermatology. 8th edn. Oxford: Blackwell Publishing. Disorders of hair. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. 2010;66.
Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27(5):389–395.
Walter K. Common causes of hair loss. JAMA. 2022;328(7):686.
Grover C, Khurana A. Telogen effluvium. Indian J Dermatol Venereol Leprol. 2013; 79(5):591-603.
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: A systematic review. Clin Cosmet Investig Dermatol. 2015;8:397–403.
Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35(1):22-7.
Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen effluvium: A review of the literature. Cureus. 2020;12(5): e8320.
Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. Faseb J. 2008;22(6):1725–36.
Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489-98.
Diani AR, Mulholland MJ, Shull KL, Kubicek M F, Johnson GA, Schostarez HJ, et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab. 1992;74(2):345-50.
Demay MB. The hair cycle and vitamin D receptor Arch Biochem Biophys. 2012;523(1):19–21.
Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: A review. Dermatol Ther (Heidelb). 2019;9(1):51-70.
Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24.
Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: A comprehensive review. Autoimmun Rev. 2015;14(2):81–89.